SCHEMBL4606525

SCHEMBL4606525

CCC(=O)Nc1ccc(Oc2ccccc2Nc2ccc(F)cc2)cc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSV O60911 2/20 0.47
CTSL P07711 2/20 0.47
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 3/20 0.45
PKM P14618 1/20 0.45
PYGM P11217 2/20 0.44
CYP19A1 P11511 1/20 0.44
PYGL P06737 1/20 0.43
POLB P06746 2/20 0.43
MTNR1B P49286 2/20 0.43
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.43
MTNR1A P48039 1/20 0.43
ATM Q13315 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
EGFR P00533 2/20 0.43
ERBB4 Q15303 2/20 0.43
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4604961 0.94 ALDH1A1 (0.48) CTSVCTSLALDH1A1KDM4EPKM
SCHEMBL4604249 0.88 POLB (0.54) ALDH1A1KDM4EPKMPYGMPYGL
SCHEMBL4604342 0.84 KDM4E (0.49) ALDH1A1KDM4EPKMPYGMPYGL
SCHEMBL4603669 0.83 ALDH1A1 (0.53) ALDH1A1KDM4EPKMPYGMPOLB
SCHEMBL4606880 0.83 KMT2A (0.57) ALDH1A1KDM4EPKMPYGMPYGL
SCHEMBL4603683 0.82 PYGM (0.62) PYGMPYGLMAPTMEN1KMT2A
SCHEMBL4606539 0.82 MTNR1B (0.50) ALDH1A1KDM4EPKMPYGMPYGL
SCHEMBL4606033 0.81 RORC (0.47) CTSVCTSLALDH1A1KDM4EPKM
SCHEMBL4619861 0.80 KDM4E (0.47) ALDH1A1KDM4EPKMLMNAKMT2A
SCHEMBL4606034 0.80 IGF2BP2 (0.51) ALDH1A1KDM4EPKMPYGMPYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 CTSV 3336/4885CTSL 3820/4885ALDH1A1 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.